share_log

シンバイオ製薬---2Q抗ウイルス薬SyB V-1901について、グローバル臨床試験の検討や実施を推進

Shin-Bio Pharmaceuticals正在推動2Q抗病毒藥物SyB V-1901進行全球臨床試驗的研究和實施

Fisco日本 ·  08/01 21:58

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論